Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S M Snapinn

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Health Services Research|February 1, 1986
A method for constructing case-mix indexes, with application to hospital length of stayR H Shachtman, S M Snapinn, D Quade, et al.
Archives of Internal Medicine|February 12, 1996
Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual componentsJ H MacKay, K E Arcuri, A I Goldberg, et al.
European Heart Journal|January 17, 2002
An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUSD A Morrow, E M Antman, S M Snapinn, et al.
American Heart Journal|July 1, 1996
Benefit of converting enzyme inhibition on left ventricular volumes and ejection fraction in patients receiving beta-blockade after myocardial infarction. CONSENSUS II multiecho study groupV V Bonarjee, S Carstensen, K Caidahl, et al.
The American Journal of Cardiology|March 1, 1989
Hemodynamic effects of lisinopril after long-term administration in congestive heart failureC K Stone, B F Uretsky, T J Linnemeier, et al.
Ugeskrift for Laeger|October 17, 2001
[Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy]H H Parving, B M Brenner, M E Cooper, et al.
The New England Journal of Medicine|September 22, 2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyB M Brenner, M E Cooper, D de Zeeuw, et al.
Statistics in Medicine|March 1, 1993
Monitoring of clinical trials and interim analyses from a drug sponsor's point of viewG W Williams, R L Davis, A J Getson, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Health Services Research|February 1, 1986
A method for constructing case-mix indexes, with application to hospital length of stayR H Shachtman, S M Snapinn, D Quade, et al.
Archives of Internal Medicine|February 12, 1996
Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual componentsJ H MacKay, K E Arcuri, A I Goldberg, et al.
European Heart Journal|January 17, 2002
An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUSD A Morrow, E M Antman, S M Snapinn, et al.
American Heart Journal|July 1, 1996
Benefit of converting enzyme inhibition on left ventricular volumes and ejection fraction in patients receiving beta-blockade after myocardial infarction. CONSENSUS II multiecho study groupV V Bonarjee, S Carstensen, K Caidahl, et al.
The American Journal of Cardiology|March 1, 1989
Hemodynamic effects of lisinopril after long-term administration in congestive heart failureC K Stone, B F Uretsky, T J Linnemeier, et al.
Ugeskrift for Laeger|October 17, 2001
[Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy]H H Parving, B M Brenner, M E Cooper, et al.
The New England Journal of Medicine|September 22, 2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyB M Brenner, M E Cooper, D de Zeeuw, et al.
Statistics in Medicine|March 1, 1993
Monitoring of clinical trials and interim analyses from a drug sponsor's point of viewG W Williams, R L Davis, A J Getson, et al.
Pageof 2